Definition:Genomics
🧬 Genomics — the study of an organism's complete set of DNA, including gene interactions and their influence on health outcomes — poses profound questions for the insurance industry, particularly in life insurance, health insurance, and critical illness underwriting, where an individual's genetic profile can reveal predispositions to diseases that directly affect mortality and morbidity risk. Unlike traditional medical underwriting factors such as blood pressure or family history, genomic data offers predictive power at the molecular level, creating both opportunities for more precise risk classification and deep ethical and regulatory challenges around fairness and access to coverage.
🔬 The practical intersection of genomics and insurance revolves around whether insurers can — or should — use genetic test results when assessing applicants. In the United Kingdom, the industry voluntarily adheres to a Code on Genetic Testing and Insurance that, with limited exceptions, prevents insurers from requiring or using predictive genetic test results for most policies. In the United States, the Genetic Information Nondiscrimination Act (GINA) prohibits the use of genetic information in health insurance underwriting but notably does not extend to life, disability, or long-term care insurance, leaving a patchwork of state-level protections. Markets such as Canada, Australia, and several European jurisdictions have adopted moratoria or legislative bans of varying scope. A core concern for insurers is adverse selection: if applicants who know they carry high-risk genetic markers purchase larger amounts of coverage while insurers remain blind to that information, the resulting information asymmetry can destabilize pricing and reserving assumptions.
⚖️ Beyond underwriting, genomics is reshaping insurance product development and claims management. Some insurtechs and forward-thinking carriers are exploring wellness-oriented life and health products that incorporate voluntary genetic screening as part of a broader preventive health program — rewarding policyholders who engage with early interventions rather than penalizing genetic predisposition. The actuarial profession is actively debating how to incorporate genomic risk factors into actuarial models without running afoul of anti-discrimination norms. As genetic testing becomes cheaper and more widespread, the pressure on regulators to establish clear, consistent frameworks will intensify, making genomics one of the most consequential emerging issues at the intersection of science, ethics, and insurance regulation.
Related concepts: